Novo Nordisk launches Wegovy in UAE 

Key Takeaways

• The UAE has approved the oral Wegovy pill, positioning the country as a regional leader in offering innovative obesity treatments alongside the previously approved injectable form (gulfnews.com).
• Wegovy (semaglutide) is a GLP‑1 receptor agonist with demonstrated efficacy in long‑term weight loss, maintenance, and reduction of cardiovascular risk when paired with diet and exercise (gulfnews.com).
• This launch supports Novo Nordisk’s global rollout strategy for its oral weight‑loss product outside the U.S., where it already boosted first‑quarter performance and drove raised full‑year guidance (marketscreener.com)